Tango Therapeutics, Inc. (TNGX) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 53.81M | 3.18M | 5.39M | 4.12M | 11.61M | 19.88M | 6.47M | 5.43M | 10.73M | 14.6M |
| Revenue Growth % | -100% | -100% | 363.61% | -84% | -16.67% | -24.19% | 8.15% | 36.15% | 12.23% | -15.29% | 55.09% | 152.95% |
| Cost of Goods Sold | 463K | 479K | 0 | 625K | 0 | 0 | 0 | 0 | 0 | 0 | 613K | 1.51M |
| COGS % of Revenue | - | - | - | 19.65% | - | - | - | - | - | - | 5.71% | 10.33% |
| Gross Profit | -463K | -479K | 53.81M | 2.56M | 5.39M | 4.12M | 11.61M | 19.88M | 6.47M | 5.43M | 10.12M | 13.09M |
| Gross Margin % | - | - | 100% | 80.35% | 100% | 100% | 100% | 100% | 100% | 100% | 94.29% | 89.67% |
| Gross Profit Growth % | -108.59% | -111.63% | 363.61% | -87.14% | -16.67% | -24.19% | 14.7% | 51.83% | 50.21% | 9.52% | 77.53% | 157.42% |
| Operating Expenses | 48.31M | 41.38M | 39.74M | 43.52M | 47.92M | 45.03M | 44.48M | 49.43M | 48.73M | 40.44M | 35.74M | 36.34M |
| OpEx % of Revenue | - | - | 73.85% | 1368.22% | 888.76% | 1093.68% | 383.26% | 248.69% | 752.99% | 744.69% | 333.07% | 248.92% |
| Selling, General & Admin | 15.23M | 9.76M | 8.92M | 11.34M | 11.48M | 11.09M | 11.22M | 10.77M | 10.66M | 9.11M | 8.6M | 7.67M |
| SG&A % of Revenue | - | - | 16.58% | 356.52% | 212.91% | 269.37% | 96.68% | 54.2% | 164.75% | 167.65% | 80.1% | 52.51% |
| Research & Development | 33.07M | 33.28M | 30.82M | 32.18M | 36.44M | 33.94M | 33.26M | 38.65M | 38.06M | 31.34M | 27.15M | 28.67M |
| R&D % of Revenue | - | - | 57.27% | 1011.69% | 675.85% | 824.31% | 286.58% | 194.49% | 588.24% | 577.04% | 252.97% | 196.4% |
| Other Operating Expenses | 0 | -1000K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -48.77M | -41.86M | 14.07M | -40.97M | -42.53M | -40.91M | -32.88M | -29.55M | -42.26M | -35.01M | -25.63M | -23.25M |
| Operating Margin % | - | - | 26.15% | -1287.87% | -788.76% | -993.68% | -283.26% | -148.69% | -652.99% | -644.69% | -238.78% | -159.25% |
| Operating Income Growth % | -14.67% | -2.33% | 142.8% | -38.63% | -0.65% | -16.84% | -28.3% | -27.12% | -39.52% | -14.55% | 14.36% | 7.76% |
| EBITDA | -48.31M | -41.38M | 14.63M | -40.34M | -41.91M | -40.29M | -32.26M | -28.92M | -41.63M | -34.4M | -25.01M | -21.74M |
| EBITDA Margin % | - | - | 27.18% | -1268.22% | -777.23% | -978.63% | -277.9% | -145.51% | -643.33% | -633.33% | -233.07% | -148.92% |
| EBITDA Growth % | -15.27% | -2.72% | 145.35% | -39.5% | -0.67% | -17.14% | -28.96% | -33.03% | -44.41% | -18.14% | 12.86% | 11.33% |
| D&A (Non-Cash Add-back) | 463K | 479K | 555K | 625K | 622K | 620K | 622K | 632K | 625K | 617K | 613K | 1.51M |
| EBIT | -48.77M | -41.86M | 14.07M | -38.82M | -42.53M | -40.91M | -32.88M | -29.55M | -42.26M | -35.01M | -22.24M | -20.65M |
| Net Interest Income | 2.18M | 1.68M | 1.1M | 1.24M | 1.61M | 1.81M | 1.81M | 2.07M | 2.2M | 2.24M | 1.87M | 1.45M |
| Interest Income | 2.18M | 1.68M | 1.1M | 1.24M | 1.61M | 1.81M | 1.81M | 2.07M | 2.2M | 2.24M | 1.87M | 1.45M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 3.26M | 3.06M | 1.8M | 2.15M | 2.69M | 3.29M | 3.77M | 4.07M | 4.38M | 4.3M | 3.39M | 2.6M |
| Pretax Income | -45.51M | -38.8M | 15.87M | -38.82M | -39.84M | -37.62M | -29.11M | -25.49M | -37.87M | -30.72M | -22.24M | -20.65M |
| Pretax Margin % | - | - | 29.5% | -1220.31% | -738.91% | -913.8% | -250.82% | -128.23% | -585.29% | -565.57% | -207.23% | -141.43% |
| Income Tax | 1K | -55K | -10K | 35K | 34K | 49K | 54K | 65K | 40K | 47K | 23K | 64K |
| Effective Tax Rate % | -0% | 0.14% | -0.06% | -0.09% | -0.09% | -0.13% | -0.19% | -0.26% | -0.11% | -0.15% | -0.1% | -0.31% |
| Net Income | -45.51M | -38.75M | 15.88M | -38.85M | -39.88M | -37.67M | -29.17M | -25.55M | -37.91M | -30.76M | -22.26M | -20.71M |
| Net Margin % | - | - | 29.52% | -1221.41% | -739.54% | -914.99% | -251.29% | -128.56% | -585.91% | -566.43% | -207.45% | -141.87% |
| Net Income Growth % | -14.14% | -2.86% | 154.46% | -52.06% | -5.17% | -22.45% | -31.01% | -23.38% | -35.37% | -5.86% | 23.36% | 16.69% |
| Net Income (Continuing) | -45.51M | -38.75M | 15.88M | -38.85M | -39.88M | -37.67M | -29.17M | -25.55M | -37.91M | -30.76M | -22.26M | -20.71M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.32 | -0.30 | 0.14 | -0.35 | -0.36 | -0.34 | -0.27 | -0.24 | -0.35 | -0.32 | -0.23 | -0.23 |
| EPS Growth % | 11.11% | 11.76% | 151.85% | -45.83% | -2.86% | -6.25% | -17.39% | -4.35% | -20.69% | 3.03% | 28.13% | 17.86% |
| EPS (Basic) | -0.32 | -0.30 | 0.14 | -0.35 | -0.36 | -0.34 | -0.27 | -0.24 | -0.35 | -0.32 | -0.23 | -0.23 |
| Diluted Shares Outstanding | 143.58M | 116.17M | 110.97M | 110.54M | 110.3M | 108.68M | 108.51M | 108.31M | 108.17M | 95.8M | 97.03M | 88.35M |
| Basic Shares Outstanding | 143.58M | 116.17M | 110.97M | 110.54M | 110.3M | 108.68M | 108.51M | 108.31M | 108.17M | 95.8M | 97.03M | 88.35M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |